Aktienanalyse zu Agios Pharmaceuticals, Inc. (AGIO)AGIOAgios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Agios Pharmaceuticals is a good buy right now due to its significant revenue growth of 259.1% year-over-year in Q2, reaching $44.75 million, and a favorable forward P/E ratio of 2.47, suggesting potential undervaluation. However, the main risk is the negative net income of $100.7 million in Q2, which indicates ongoing profitability challenges.

11 analysts cover AGIO: 9 rate it Buy, 2 Hold and 0 Sell. The average price target is 36.14.